Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junya Yamaguchi

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Science Translational Medicine|April 15, 2026
On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastomaJunya Yamaguchi, Keisuke Watanabe, Akihiro Nakamura, et al.
Cancer Medicine|December 8, 2022
CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphomaJunya Yamaguchi, Fumiharu Ohka, Chalise Lushun, et al.
Cancer Research|August 1, 2021
Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant GliomasKosuke Aoki, Hiromichi Suzuki, Takashi Yamamoto, et al.
Japanese Journal of Clinical Oncology|September 3, 2024
Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study groupKazuya Motomura, Keita Sasaki, Narushi Sugii, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Science Translational Medicine|April 15, 2026
On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastomaJunya Yamaguchi, Keisuke Watanabe, Akihiro Nakamura, et al.
Cancer Medicine|December 8, 2022
CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphomaJunya Yamaguchi, Fumiharu Ohka, Chalise Lushun, et al.
Cancer Research|August 1, 2021
Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant GliomasKosuke Aoki, Hiromichi Suzuki, Takashi Yamamoto, et al.
Japanese Journal of Clinical Oncology|September 3, 2024
Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study groupKazuya Motomura, Keita Sasaki, Narushi Sugii, et al.
Pageof 8